Thus the differential translocation of the 43, 31 and 26 kDa forms of dystroglycan to the nucleus, coupled with the role of androgens, provides a potential mechanism for dystroglycan to have a regulatory role in prostate cancer progression through altering as yet unidentified nuclear functions. The gene discussed is DAG1; the disease is Familial prostate cancer.